BAP1 and uveal melanoma: However, it is again critical to note that BAP1 mutations are more prevalent and have greater prognostic relevance in uveal melanoma compared to cutaneous melanoma, suggesting that the therapeutic potential of Niraparib in cutaneous melanoma may be more limited.